Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings-Reference-Cited by-同舟云学术

Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings

Published:2024-03-21 Issue:8 Volume:26 Page:2070-2074
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Martin-Quesada Ana Isabel^ORCID,Llabres-Valentí Elisenda,Montesdeoca-Godoy Cristina María,Martín-Abreu Carla,Alemán-Sánchez Cristina,Rodríguez-Pérez Natalia,Herrero-Márquez Alicia,Cruz-Jurado Josefina,Hernández-Sosa María,Marrero-García Melody,DelPino-Hernández Cristina Victoria,Hernández-Sarmiento Samuel José,Rodríguez-Capote Alejandra,Pérez-Méndez Lina,Núñez-Hernández Isaac

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03430-7.pdf

Reference13 articles.

1. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer [Internet]. 2007;110(4):876–84. https://doi.org/10.1002/cncr.22836.

2. Spring LM, Arfe A. Pathological complete response (pCR) after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Patient-level meta-analyses of over 27,000 patients. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium (SABCS) Dec. 2018. p. 4–8.

3. Shepherd JH, Ballman K, Polley M-YC, Campbell JD, Fan C, Selitsky S, et al. CALGB 40603 (alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple negative breast cancer. J Clin Oncol [Internet]. 2022;40(12):1323–34. https://doi.org/10.1200/jco.21.01506.

4. Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. Ann Oncol [Internet]. 2018;29(12):2341–7. https://doi.org/10.1093/annonc/mdy460.

5. Sharma P, Kimler BF, O’Dea A, Nye L, Wang YY, Yoder R, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res [Internet]. 2021;27(4):975–82. https://doi.org/10.1158/10780432.ccr-20-3646.